X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20649) 20649
Publication (2071) 2071
Newsletter (922) 922
Book Review (398) 398
Newspaper Article (231) 231
Magazine Article (170) 170
Book Chapter (143) 143
Transcript (86) 86
Book / eBook (56) 56
Trade Publication Article (33) 33
Conference Proceeding (19) 19
Dissertation (19) 19
Web Resource (15) 15
Reference (4) 4
Data Set (3) 3
Paper (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16069) 16069
index medicus (8240) 8240
hiv infections - drug therapy (6830) 6830
male (6567) 6567
female (5956) 5956
protease inhibitors (5923) 5923
animals (5030) 5030
proteases (4679) 4679
adult (4623) 4623
hiv protease inhibitors - therapeutic use (4600) 4600
infectious diseases (3778) 3778
anti-hiv agents - therapeutic use (3735) 3735
middle aged (3494) 3494
pharmacology & pharmacy (3386) 3386
protease inhibitors - therapeutic use (3331) 3331
hiv (3293) 3293
drug therapy, combination (3019) 3019
immunology (2759) 2759
research (2586) 2586
health aspects (2288) 2288
hiv infections - virology (2187) 2187
virology (2177) 2177
viral load (2165) 2165
treatment outcome (2057) 2057
reverse transcriptase inhibitors - therapeutic use (2024) 2024
proteins (1961) 1961
drug therapy (1936) 1936
antiretroviral therapy (1851) 1851
mice (1787) 1787
research article (1716) 1716
hiv-1 - drug effects (1645) 1645
cd4 lymphocyte count (1579) 1579
care and treatment (1556) 1556
aids (1553) 1553
antiviral agents (1546) 1546
microbiology (1540) 1540
protease inhibitors - pharmacology (1527) 1527
medicine (1517) 1517
antiviral agents - therapeutic use (1498) 1498
protease (1431) 1431
analysis (1428) 1428
aged (1413) 1413
hiv infection (1398) 1398
therapy (1395) 1395
ritonavir - therapeutic use (1390) 1390
protease inhibitor (1384) 1384
hiv protease inhibitors - adverse effects (1358) 1358
multidisciplinary sciences (1356) 1356
antiretroviral therapy, highly active (1331) 1331
biochemistry & molecular biology (1319) 1319
hiv-1 - genetics (1267) 1267
mutation (1256) 1256
physiological aspects (1251) 1251
human-immunodeficiency-virus (1235) 1235
cancer (1208) 1208
risk factors (1171) 1171
oncology (1165) 1165
science (1165) 1165
infection (1161) 1161
highly active antiretroviral therapy (1139) 1139
apoptosis (1130) 1130
ritonavir (1108) 1108
article (1097) 1097
genotype (1086) 1086
hiv protease inhibitors - administration & dosage (1083) 1083
hiv infections - complications (1081) 1081
enzymes (1072) 1072
rats (1057) 1057
hiv-1 (1056) 1056
human immunodeficiency virus--hiv (1049) 1049
expression (1026) 1026
genetic aspects (1009) 1009
hiv infections - immunology (978) 978
drug resistance (966) 966
in-vitro (961) 961
biology (937) 937
adolescent (927) 927
cell biology (920) 920
drug interactions (907) 907
clinical trials as topic (905) 905
hiv protease inhibitors - pharmacology (902) 902
inhibitors (895) 895
anti-hiv agents - adverse effects (878) 878
rna, viral - blood (876) 876
time factors (874) 874
biochemistry (830) 830
antiretroviral drugs (827) 827
viruses (826) 826
chemistry, medicinal (824) 824
hepatitis c virus (816) 816
inflammation (814) 814
medical research (813) 813
active antiretroviral therapy (793) 793
gene expression (793) 793
hepatitis c (793) 793
drug resistance, viral (791) 791
resistance (786) 786
virus diseases (786) 786
anti-hiv agents - administration & dosage (780) 780
hepatitis c, chronic - drug therapy (747) 747
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21176) 21176
Spanish (242) 242
Russian (215) 215
French (198) 198
German (174) 174
Japanese (122) 122
Italian (32) 32
Polish (28) 28
Chinese (23) 23
Dutch (13) 13
Hungarian (12) 12
Portuguese (12) 12
Danish (8) 8
Ukrainian (8) 8
Czech (6) 6
Turkish (4) 4
Finnish (3) 3
Norwegian (3) 3
Serbian (3) 3
Swedish (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Lithuanian (2) 2
Romanian (2) 2
Slovak (2) 2
Arabic (1) 1
Croatian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hepatology, ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 471
Journal Article
Journal Article
Liver International, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 47 - 57
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Hepatology, ISSN 0270-9139, 12/2008, Volume 48, Issue 6, pp. 1769 - 1778
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | INCRETIN HORMONES | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | TYPE-2 DIABETES-MELLITUS | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article